Summarized by Masters of Longevity from Longevity Technology.
Bexorg-focused piece outlining a funded research program to advance a human brain perfusion platform for longer-term, longitudinal pharmacology studies.
Key Takeaways
- ARPA-H granted up to $28.3 million to fund a three-phase, 36-month project to extend BrainEx perfusion from 24 hours to up to two weeks.
- The project will validate sustained brain physiology under automated perfusion and compare BrainEx drug responses with known clinical outcomes.
